A recent study showed that CmAb-(IL10)2, an IL-10 fusion protein derived from cetuximab, prevents dendritic cell-induced apoptosis of CD8+ tumor-infiltrating lymphocytes by controlling the production of IFN-γ [133]. Here, IL10 is linked to neoplasm.